TY - JOUR
T1 - Cyclosporin A and FK506
T2 - molecular mechanisms of immunosuppression and probes for transplantation biology
AU - Bierer, Barbara E.
AU - Holländer, Georg
AU - Fruman, David
AU - Burakoff, Steven J.
N1 - Funding Information:
DAF. is a Howard Hughes Medical Institute Predoctonl Fellow. B.E.B. is the recipient of an Established Investigator award from the American Heart Association. This work n~s supported by grants Al32514 and CA 39542 from the National Institutes of Health.
PY - 1993/10
Y1 - 1993/10
N2 - The microbial products cyclosporin A (CsA), FK506 and rapamycin are potent immunosuppressive agents. The introduction of CsA in the early 1970's significantly improved the outcome of organ and bone marrow allograft transplantation and advanced therapeutic options in autoimmune diseases. FK506 appears to have a higher therapeutic index than CsA, and has been used with encouraging results in clinical transplantation trials. FK506 and CsA, although structurally unrelated, appear to target similar signal transduction pathways in hematopoietic cells by inhibiting the action of calcineurin, a serine/threonine phosphatase. A structural analog of FK506, rapamycin, inhibits cellular function by a different molecular mechanism. These agents have advanced our understanding of signal transmission pathways in lymphocyte activation.
AB - The microbial products cyclosporin A (CsA), FK506 and rapamycin are potent immunosuppressive agents. The introduction of CsA in the early 1970's significantly improved the outcome of organ and bone marrow allograft transplantation and advanced therapeutic options in autoimmune diseases. FK506 appears to have a higher therapeutic index than CsA, and has been used with encouraging results in clinical transplantation trials. FK506 and CsA, although structurally unrelated, appear to target similar signal transduction pathways in hematopoietic cells by inhibiting the action of calcineurin, a serine/threonine phosphatase. A structural analog of FK506, rapamycin, inhibits cellular function by a different molecular mechanism. These agents have advanced our understanding of signal transmission pathways in lymphocyte activation.
UR - http://www.scopus.com/inward/record.url?scp=0027527305&partnerID=8YFLogxK
U2 - 10.1016/0952-7915(93)90135-F
DO - 10.1016/0952-7915(93)90135-F
M3 - Article
C2 - 7694595
AN - SCOPUS:0027527305
SN - 0952-7915
VL - 5
SP - 763
EP - 773
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 5
ER -